Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Director Sells $86,927.90 in Stock

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRXGet Free Report) Director Molly Harper sold 5,333 shares of the firm’s stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $16.30, for a total transaction of $86,927.90. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Catalyst Pharmaceuticals Stock Down 3.4 %

NASDAQ:CPRX opened at $15.76 on Friday. The company has a fifty day simple moving average of $15.66 and a two-hundred day simple moving average of $15.22. The company has a market cap of $1.86 billion, a price-to-earnings ratio of 29.19, a price-to-earnings-growth ratio of 1.36 and a beta of 0.73. Catalyst Pharmaceuticals, Inc. has a 52 week low of $11.48 and a 52 week high of $17.50.

Catalyst Pharmaceuticals (NASDAQ:CPRXGet Free Report) last posted its quarterly earnings results on Wednesday, May 8th. The biopharmaceutical company reported $0.31 EPS for the quarter, hitting the consensus estimate of $0.31. The business had revenue of $98.51 million during the quarter, compared to the consensus estimate of $97.24 million. Catalyst Pharmaceuticals had a net margin of 15.83% and a return on equity of 25.08%. On average, analysts expect that Catalyst Pharmaceuticals, Inc. will post 1.78 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the stock. Oppenheimer reiterated an “outperform” rating and issued a $29.00 target price on shares of Catalyst Pharmaceuticals in a report on Thursday. HC Wainwright reiterated a “buy” rating and issued a $26.00 target price on shares of Catalyst Pharmaceuticals in a report on Monday. Citigroup assumed coverage on shares of Catalyst Pharmaceuticals in a report on Thursday, March 14th. They issued a “buy” rating and a $27.00 target price for the company. Cantor Fitzgerald reiterated an “overweight” rating and issued a $34.00 target price on shares of Catalyst Pharmaceuticals in a report on Friday, March 22nd. Finally, TheStreet upgraded shares of Catalyst Pharmaceuticals from a “c+” rating to a “b” rating in a report on Tuesday, March 12th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $26.71.

Check Out Our Latest Stock Report on CPRX

Hedge Funds Weigh In On Catalyst Pharmaceuticals

Several institutional investors have recently modified their holdings of the business. Ameritas Investment Partners Inc. grew its stake in shares of Catalyst Pharmaceuticals by 6.9% in the first quarter. Ameritas Investment Partners Inc. now owns 11,116 shares of the biopharmaceutical company’s stock worth $177,000 after acquiring an additional 720 shares in the last quarter. GAMMA Investing LLC lifted its position in shares of Catalyst Pharmaceuticals by 72.9% during the 1st quarter. GAMMA Investing LLC now owns 1,942 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 819 shares during the last quarter. State Board of Administration of Florida Retirement System lifted its position in shares of Catalyst Pharmaceuticals by 4.7% during the 3rd quarter. State Board of Administration of Florida Retirement System now owns 28,660 shares of the biopharmaceutical company’s stock worth $335,000 after purchasing an additional 1,290 shares during the last quarter. Mutual of America Capital Management LLC lifted its position in shares of Catalyst Pharmaceuticals by 9.7% during the 1st quarter. Mutual of America Capital Management LLC now owns 19,241 shares of the biopharmaceutical company’s stock worth $307,000 after purchasing an additional 1,701 shares during the last quarter. Finally, PNC Financial Services Group Inc. lifted its position in shares of Catalyst Pharmaceuticals by 15.3% during the 4th quarter. PNC Financial Services Group Inc. now owns 12,960 shares of the biopharmaceutical company’s stock worth $218,000 after purchasing an additional 1,719 shares during the last quarter. Institutional investors and hedge funds own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Company Profile

(Get Free Report)

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.

See Also

Insider Buying and Selling by Quarter for Catalyst Pharmaceuticals (NASDAQ:CPRX)

Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.